Analytical Performance Evaluated for Troponin T Gen 5 Assay
By LabMedica International staff writers Posted on 05 Sep 2019 |
Image: The Elecsys Troponin T Gen 5 STAT assay (Photo courtesy of Roche Diagnostics).
Increased blood concentrations of cardiac troponin (cTn) I and T are indicative of myocardial injury and are the preferred biomarkers for diagnosing acute myocardial infarction (AMI). The diagnosis of AMI requires a rise and/or fall in serial cTn measurements, in addition to other clinical features.
The introduction of high-sensitivity assays has enabled the rapid detection of subtle changes in cTn and facilitated earlier decision-making in the management of patients with suspected AMI, compared with less sensitive contemporary assays. These newer assays which can measure cTn concentrations 5 to 10 times lower than current assays and do so with improved analytical imprecision.
A team of Medical Scientists collaborating with the University of California San Diego Health (San Diego, CA, USA) analyzed the performance of the Elecsys Troponin T Gen 5 STAT assay. This assay is an electrochemiluminescence sandwich immunoassay, which uses two antibodies to form a sandwich complex with cTnT. A biotinylated monoclonal anti-cTnT-specific antibody and a monoclonal anti-cTnT-specific antibody labeled with ruthenium react to form a sandwich complex. Precision was evaluated per Clinical and Laboratory Standards Institute (CLSI) EP05-A2 using lithium-heparin plasma/quality control samples on Roche cobas e 411/cobas e 601 analyzers.
The scientists reported that the coefficients of variation (CV) for repeatability/intermediate precision were 0.7–5.6%/1.4–10.3% (cobas e 411; mean cardiac troponin T [cTnT]: 7.3–9,341 ng/L) and 0.7–3.0%/1.5–6.4% (cobas e 601; mean cTnT: 7.4–9,455 ng/L). There was no cross-reactivity with skeletal muscle troponin T (≤ 10,000 ng/L), skeletal muscle troponin I (≤ 100,000 ng/L), cardiac troponin I (≤ 10,000 ng/L), or human troponin C (≤ 80,000 ng/L). No interference was observed with biotin (≤ 20 ng/mL) or 34 drugs. The specified limit of blank and limit of detection were 3 ng/L and 5 ng/L, respectively, on the cobas e 411 analyzer, and 2.5 ng/L and 3 ng/L, respectively, on the cobas e 601 analyzer.
The authors concluded that the Elecsys TnT Gen 5 STAT assay demonstrated good analytical performance on cobas e 411 and cobas e 601 analyzers, with a CV of ≤ 10% at the 99th percentile URL. These findings support the routine use of the assay in clinical laboratories in the USA. The study was published in the August 2019 issue of the journal Clinica Chimica Acta.
Related Links:
University of California San Diego Health
The introduction of high-sensitivity assays has enabled the rapid detection of subtle changes in cTn and facilitated earlier decision-making in the management of patients with suspected AMI, compared with less sensitive contemporary assays. These newer assays which can measure cTn concentrations 5 to 10 times lower than current assays and do so with improved analytical imprecision.
A team of Medical Scientists collaborating with the University of California San Diego Health (San Diego, CA, USA) analyzed the performance of the Elecsys Troponin T Gen 5 STAT assay. This assay is an electrochemiluminescence sandwich immunoassay, which uses two antibodies to form a sandwich complex with cTnT. A biotinylated monoclonal anti-cTnT-specific antibody and a monoclonal anti-cTnT-specific antibody labeled with ruthenium react to form a sandwich complex. Precision was evaluated per Clinical and Laboratory Standards Institute (CLSI) EP05-A2 using lithium-heparin plasma/quality control samples on Roche cobas e 411/cobas e 601 analyzers.
The scientists reported that the coefficients of variation (CV) for repeatability/intermediate precision were 0.7–5.6%/1.4–10.3% (cobas e 411; mean cardiac troponin T [cTnT]: 7.3–9,341 ng/L) and 0.7–3.0%/1.5–6.4% (cobas e 601; mean cTnT: 7.4–9,455 ng/L). There was no cross-reactivity with skeletal muscle troponin T (≤ 10,000 ng/L), skeletal muscle troponin I (≤ 100,000 ng/L), cardiac troponin I (≤ 10,000 ng/L), or human troponin C (≤ 80,000 ng/L). No interference was observed with biotin (≤ 20 ng/mL) or 34 drugs. The specified limit of blank and limit of detection were 3 ng/L and 5 ng/L, respectively, on the cobas e 411 analyzer, and 2.5 ng/L and 3 ng/L, respectively, on the cobas e 601 analyzer.
The authors concluded that the Elecsys TnT Gen 5 STAT assay demonstrated good analytical performance on cobas e 411 and cobas e 601 analyzers, with a CV of ≤ 10% at the 99th percentile URL. These findings support the routine use of the assay in clinical laboratories in the USA. The study was published in the August 2019 issue of the journal Clinica Chimica Acta.
Related Links:
University of California San Diego Health
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines